Levetiracetam Aristo (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. By modulating this protein, the drug stabilizes neuronal firing and reduces excessive excitability that can trigger seizures.

The specific dose of Levetiracetam Aristo is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for Levetiracetam during pregnancy and lactation are limited. The prescriber must weigh potential benefits against risks and consider alternative therapies if appropriate. Women who are pregnant or nursing should discuss treatment options with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well tolerated, has few drug‑enzyme interactions, and may be preferred when rapid titration or minimal hepatic metabolism is desired.

Store Levetiracetam Aristo at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Levetiracetam Aristo is taken orally, usually with or without food. Tablets should be swallowed whole with water. The exact administration schedule—once daily, twice daily, or more—depends on the prescriber’s dosing plan.

Serious risks include severe allergic reactions (e.g., rash, swelling, breathing difficulty), mood disturbances such as depression or suicidal thoughts, and rare blood disorders like leukopenia or thrombocytopenia. Patients should seek immediate medical attention if any of these occur.

Patients with known hypersensitivity to levetiracetam or any excipients in the tablet should avoid the product. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications without medical supervision.